Oryzon Genomics SA (ORYZF)
3.645
-0.06
(-1.49%)
USD |
OTCM |
Jun 10, 16:00
Oryzon Genomics Debt to Equity Ratio : 0.0681 for March 31, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.0681 |
| December 31, 2025 | 0.1132 |
| September 30, 2025 | 0.0866 |
| June 30, 2025 | 0.1284 |
| March 31, 2025 | 0.1464 |
| December 31, 2024 | 0.1988 |
| September 30, 2024 | 0.1619 |
| June 30, 2024 | 0.1685 |
| March 31, 2024 | 0.191 |
| December 31, 2023 | 0.2452 |
| September 30, 2023 | 0.1662 |
| June 30, 2023 | 0.2094 |
| March 31, 2023 | 0.2398 |
| December 31, 2022 | 0.3415 |
| September 30, 2022 | 0.316 |
| June 30, 2022 | 0.224 |
| March 31, 2022 | 0.247 |
| Date | Value |
|---|---|
| September 30, 2021 | 0.2029 |
| June 30, 2021 | 0.2219 |
| March 31, 2021 | 0.1693 |
| December 31, 2020 | 0.1919 |
| September 30, 2020 | 0.2041 |
| June 30, 2020 | 0.2098 |
| March 31, 2020 | 0.14 |
| December 31, 2019 | 0.2367 |
| September 30, 2019 | 0.232 |
| June 30, 2019 | 0.373 |
| March 31, 2019 | 0.3303 |
| December 31, 2018 | 0.3881 |
| September 30, 2018 | 0.5241 |
| June 30, 2018 | 0.5662 |
| March 31, 2018 | 0.6426 |
| March 31, 2016 | 0.6179 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Pharma Mar SA | 0.1904 |
| Grifols SA | 1.772 |
| ACADIA Pharmaceuticals, Inc. | 0.0407 |
| Alkermes Plc | 0.903 |
| Alnylam Pharmaceuticals, Inc. | 2.762 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 163.27M |
| Total Liabilities (Quarterly) | 26.97M |
| Shareholders Equity (Quarterly) | 120.20M |
| Current Ratio | 1.834 |
| Net Debt Paydown Yield | 0.66% |